CorMedix (CRMD) Common Equity (2010 - 2026)

CorMedix has reported Common Equity for 16 years, with the latest figure at $405.3 million in Q4 2025.

• Quarterly Common Equity rose 378.76% year-over-year to $405.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $405.3 million (up 378.76% YoY) and the FY2025 annual result came in at $405.3 million, up 378.76% from the prior year.
• Common Equity advanced to $405.3 million in Q4 2025 per CRMD's latest filing, from $374.1 million in the prior quarter.
• Over five years, Common Equity peaked at $405.3 million in Q4 2025 and troughed at $46.2 million in Q2 2024.
• A 5-year average of $107.1 million and a median of $66.1 million in 2021 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 294114.97% in 2021, down 63.9% in 2021.
• Over 5 years, Common Equity stood at $62.8 million in 2021, then dropped by 12.32% to $55.1 million in 2022, then increased by 27.39% to $70.1 million in 2023, then climbed by 20.69% to $84.7 million in 2024, then soared by 378.76% to $405.3 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $405.3 million, $374.1 million, and $220.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.